1. Gnekow AK, 1995. Recommendations of the brain tumor subcommittee for their reporting trials. Med Ped Oncol 1995, 24:104-108
2. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res, 2004; 10(11): 3728-36.
3. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15;13(4):1253-9.
4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40.
5. Narayana A, Kelly P, Golfinos et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009 Jan; 110(1):173-80.
6. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009, 52(7): 791-5.
7. Narayana, A., Kunnakkat, S., Chacko-Mathew, J., et al. Bevacizumab in recurrent highgrade pediatric gliomas. Neuro-oncology, 2010, 7 - 8.